Targeting Tau Pathology to Slow Alzheimer’s Disease Progression
페이지 정보
최고관리자 조회수 : 2,134본문
Alzheimer's disease (AD) is a neurodegenerative disease that affects the central nervous system, and is the cause of approximately 60–80% of dementia cases. Treatments currently approved for AD are designed to relieve symptoms, and do not address the underlying causes of the disease. AC Immune aims to confront the lack of disease-modifying treatments "head-on" by developing a series of compounds that are designed to target tau aggregation (a major hallmark of AD).
To learn more about these compounds, and more specifically "ACI-3024" we recently spoke with Prof. Andrea Pfeifer, the company's Chief Executive Officer.
Laura Lansdowne (LL): What do we know about tau’s role in Alzheimer’s disease? What are “tauopathies”?
